作者: 能量守恒 時間: 2025-3-21 21:24 作者: Mirage 時間: 2025-3-22 01:03
Claire Westall,Michael Gardinertion of bone marrow or peripheral blood stem cells can result in successful engraftment and possibly prolonged survival in some CML patients. Ex-vivo treatment of autologous stem cells by purging with antileukemic agents or growth in hematopoietic progenitor culture may selectively remove malignant 作者: 裝入膠囊 時間: 2025-3-22 07:37 作者: 一加就噴出 時間: 2025-3-22 10:05 作者: 火光在搖曳 時間: 2025-3-22 13:30 作者: mediocrity 時間: 2025-3-22 19:13
Therapy of chronic myelogenous leukemia with bone marrow transplantationtion of bone marrow or peripheral blood stem cells can result in successful engraftment and possibly prolonged survival in some CML patients. Ex-vivo treatment of autologous stem cells by purging with antileukemic agents or growth in hematopoietic progenitor culture may selectively remove malignant 作者: Occipital-Lobe 時間: 2025-3-22 23:30
Role of bone marrow transplantation as treatment for victims of nuclear accidentshe epithelial crypt cells, the proliferative cells that maintain the bowel mucosa. Injury to these cells by high doses of radiation leads to sloughing of the bowel mucosa, massive diarrhea, and sepsis, typically resulting in death within 6–9 days of exposure. Very high doses of total body irradiatio作者: ANTIC 時間: 2025-3-23 04:16 作者: 基因組 時間: 2025-3-23 07:29
Neha Singh,Sajaudeen Chapparbanficance is CMV interstitial pneumonia. This review will focus on recent progress in understanding the epidemiology of CMV infection and interstitial pneumonia after marrow transplantation and on new approaches for the diagnosis, treatment, and prevention of CMV infection and pneumonia.作者: Trabeculoplasty 時間: 2025-3-23 10:28 作者: 博愛家 時間: 2025-3-23 14:52 作者: 邊緣帶來墨水 時間: 2025-3-23 19:57
Bone marrow transplantation for immunodeficiency and genetic diseasesr is to review the current status of allogeneic bone marrow transplantation for the treatment of genetic diseases, as well as to summarize the present status of gene therapy, a potential future therapy for genetic diseases.作者: 彩色 時間: 2025-3-23 22:25 作者: 兇兆 時間: 2025-3-24 03:26 作者: 恭維 時間: 2025-3-24 08:10
T-cell depletion for bone marrow transplantation: Effects on graft rejection, graft-versus-host disem unrelated HLA-identical or partially matched related donors [6–10]. Preliminary results indicate that even with phenotypically identical unrelated donor-recipient pairs and the use of combination posttransplant immunosuppressive therapy, the incidence of acute GVHD exceeds 75%.作者: 誘使 時間: 2025-3-24 11:12 作者: nostrum 時間: 2025-3-24 17:56 作者: Ischemia 時間: 2025-3-24 22:47 作者: paleolithic 時間: 2025-3-24 23:47 作者: 粗糙濫制 時間: 2025-3-25 05:49
https://doi.org/10.1007/978-1-349-19286-1 BMT, while the donor-derived immune system is developing [5–8]. Therefore, BMT offers unique models of immunodeficiency wherein immunity develops if the recipients do not succumb to graft-versus-host disease (GVHD), infections, or nonmarrow organ toxicity [9–13].作者: neutral-posture 時間: 2025-3-25 09:32 作者: 駕駛 時間: 2025-3-25 14:29
Literature of Mysticism in Western Traditionated to the severity of pancytopenia and is largely independent of etiology. The prognosis of patients with severe aplastic anemia is grave with supportive care alone; approximately half die from bleeding or infection within 3–6 months, and less than 20% have hematologic recovery and prolonged survival.作者: 嫻熟 時間: 2025-3-25 17:58 作者: 無瑕疵 時間: 2025-3-25 23:56 作者: commonsense 時間: 2025-3-26 03:41 作者: 輕信 時間: 2025-3-26 06:29
Bone Marrow Transplantation978-1-4613-1493-6Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: Nebulizer 時間: 2025-3-26 08:44 作者: Classify 時間: 2025-3-26 13:52 作者: Regurgitation 時間: 2025-3-26 18:46
https://doi.org/10.1007/978-1-4613-1493-6anemia; bone marrow; diseases; immunodeficiency; infection; infections; internal medicine; leukemia; lymphom作者: Ostrich 時間: 2025-3-26 22:15
978-1-4612-8803-9Kluwer Academic Publishers 1990作者: 高談闊論 時間: 2025-3-27 01:24 作者: Legend 時間: 2025-3-27 06:11
Bone marrow transplantation for solid tumors in pediatricsmoradiotherapy, in which the dose is limited by the degree of bone marrow suppression, does not increase long-term survival for most disseminated neoplasms. Bone marrow transplantation utilizes high-dose chemoradiotherapy without regard to marrow toxicity and may be the treatment of choice for these malignancies.作者: 親密 時間: 2025-3-27 10:06 作者: capillaries 時間: 2025-3-27 13:48
https://doi.org/10.1007/978-1-349-19286-1y disorders, and inborn errors of metabolism [1–4]. The preparative regimens are designed to eliminate the “l(fā)ast” malignant clone and to suppress the host immune system. Ablation of the host immune system leaves the recipient immunologically crippled and susceptible to infections up to 2 years after作者: FAR 時間: 2025-3-27 19:27 作者: hypertension 時間: 2025-3-27 23:17 作者: cuticle 時間: 2025-3-28 05:58 作者: 喊叫 時間: 2025-3-28 08:47
Neha Singh,Sajaudeen Chapparbane [1]. Histocompatibility differences residing outside the HLA complex, however, are still sufficient to trigger, on the one hand, the immune response of the recipient with resulting graft failure and, on the other hand, the immune response of the donor with resulting graft-versus-host disease (GVHD作者: sigmoid-colon 時間: 2025-3-28 13:17
Vivid Girmitiya Sacraments and Ganga Talaoy described as hematopoietic growth factors [1–6]. Advances in molecular biological and protein purification techniques have made it possible to purify and subsequently clone the genes for an increasing number of these factors. These include the colony-stimulating factors (CSFs), first identified in作者: CESS 時間: 2025-3-28 18:09
https://doi.org/10.1007/978-1-349-17151-4stablished therapy for genetic disorders involving the progeny of both lymphoid and hematopoietic stem cells (Table 1) [3]. The purpose of this chapter is to review the current status of allogeneic bone marrow transplantation for the treatment of genetic diseases, as well as to summarize the present作者: 只有 時間: 2025-3-28 21:27 作者: 無動于衷 時間: 2025-3-29 01:39
Claire Westall,Michael Gardinerthe only curative therapy for CML. Younger recipient age and transplant in chronic phase are associated with better outcome. Some studies suggest that transplant within 1 year of diagnosis provides a greater likelihood of survival than transplant at a longer interval from diagnosis. T-lymphocyte dep作者: 碎石頭 時間: 2025-3-29 05:45 作者: FLIP 時間: 2025-3-29 07:38
Literature of an Independent Englandmoradiotherapy, in which the dose is limited by the degree of bone marrow suppression, does not increase long-term survival for most disseminated neoplasms. Bone marrow transplantation utilizes high-dose chemoradiotherapy without regard to marrow toxicity and may be the treatment of choice for these作者: Substance-Abuse 時間: 2025-3-29 12:25 作者: minaret 時間: 2025-3-29 17:19
Cancer Treatment and Researchhttp://image.papertrans.cn/b/image/189679.jpg作者: spinal-stenosis 時間: 2025-3-29 21:55 作者: Keratectomy 時間: 2025-3-30 02:16 作者: Ibd810 時間: 2025-3-30 04:23
England, Devolution, and Fictional KingdomsOver 2000 allogeneic bone marrow transplants are reported in persons with acute lymphoblastic leukemia [reviewed in 1–6]. Results depend on remission status and age and are summarized in Table 1.作者: Wordlist 時間: 2025-3-30 10:08 作者: 用肘 時間: 2025-3-30 13:27 作者: gustation 時間: 2025-3-30 18:23 作者: irritation 時間: 2025-3-30 21:37
Bone marrow transplantation: Introduction and overview1–5]. Three sources of hematopoietic cells can be used: . bone marrow from a related or unrelated donor, . marrow from a genetically identical twin, or . bone marrow or peripheral blood stem cells. Over 4000 patients per year receive allogeneic bone marrow transplants at more than 250 centers worldw作者: Acquired 時間: 2025-3-31 00:53 作者: 尖牙 時間: 2025-3-31 06:34
Chronic graft-versus-host diseasetransplant centers has expanded to more than 200 institutions [1,2]. Utilization will continue to increase as the number of available marrow donors increases through selection of suitable HLA-nonidentical family or unrelated marrow donors [3–5].作者: 詞根詞綴法 時間: 2025-3-31 10:26
T-cell depletion for bone marrow transplantation: Effects on graft rejection, graft-versus-host disenosuppressive therapy with cyclosporine or methotrexate, moderate to severe acute GVHD develops in approximately 45% of transplant recipients with an HLA-identical sibling donor [4] and in >75% of patients from HLA-nonidentical relatives [5]. Recently, bone marrow transplants have been performed fro作者: 遭受 時間: 2025-3-31 16:59 作者: 殘忍 時間: 2025-3-31 17:48
